- Home
- EAD vs AUTL Comparison
EAD vs AUTL Comparison
Compare EAD & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | EAD | AUTL |
|---|---|---|
| Founded | 2003 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.8M | 368.6M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | EAD | AUTL |
|---|---|---|
| Price | $6.89 | $1.55 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $8.33 |
| AVG Volume (30 Days) | 178.9K | ★ 3.9M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 8.91% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $51,128,000.00 |
| Revenue This Year | N/A | $658.11 |
| Revenue Next Year | N/A | $91.34 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $5.69 | $1.11 |
| 52 Week High | $6.81 | $3.11 |
Technical Indicators
Market Signals| Indicator | EAD | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 54.87 | 58.56 |
| Support Level | $6.84 | $1.31 |
| Resistance Level | $6.90 | $1.61 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 88.00 | 85.37 |
Price Performance
Historical ComparisonAbout EAD Allspring Income Opportunities Fund
Allspring Income Opportunities Fund is a diversified closed-end management investment company. Its products and services are mutual funds, closed-end funds, managed accounts services, and variable trust funds. The fund's objective is a high level of current income and capital appreciation. Its portfolio of investments is Commercial services, healthcare services, Food, Pharmaceuticals, Energy, Oil & gas, Pipelines, Diversified financial services, and Others.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.